Daryl Lindsey
November 30, 2016 1:22 pm

The Food and Drug Administration approved phase-3 clinical trials to treat Post Traumatic Stress Disorder using a surprising drug: Ecstasy.

The 230-patient trial is the third step toward making the recreational drug, also known as MDMA, a prescription treatment for PTSD as early as 2021.

During the first two trials, doctors gave patients three doses of the drug over 8-hour periods. The patients relaxed on futons in rooms full of candles and soft music. At the completion of the trial, two-thirds of patients “no longer met the criteria for PTSD,” the study claims.

Many doctors, like psychologist Andrew Parrot, are skeptical about using Ecstacy for clinical use.


Others say it’s working, and the effects on people with PTSD could be life-changing and life-saving.

Hopefully, this new research will lead to better lives for many people.